Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levoketoconazole DDI with Metformin in Healthy Subjects
NCT03880825Phase 1Completed
- Sponsor
- Strongbridge Biopharma
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of levoketoconazole in Cushing syndrome, sponsored by Strongbridge Biopharma. Primary endpoints: Maximum observed plasma concentration of metformin at 48 hours, Time to maximum concentration of metformin at 48 hours and 1 more. Started Mar 2019; status: completed.
02
Drugs
levoketoconazole
03
Conditions
Cushing syndrome
Beyond the preview
Go deeper on NCT03880825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880825.